EUVIMEDEUVIMED entdecken
Crossref

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study

Leandro Blas iD, Masaki Shiota iD, Hideaki Miyake, Masayuki Takahashi, Mototsugu Oya, Norihiko Tsuchiya iD, Naoya Masumori iD, Hideyasu Matsuyama, Wataru Obara iD, Nobuo Shinohara, Kiyohide Fujimoto iD, Masahiro Nozawa und 16 weitere

International Journal of Urology · 2023

DOI: 10.1111/iju.15265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2023. Verfasst von Leandro Blas und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Ono Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study is part of the S NPs in Ni volumab P D‐1 inhibitor for RCC (SNiP‐RCC). Here we aimed to reveal clinical factors for tumor response, progression, and survival in nivolumab for advanced clear cell renal cell carcinoma (RCC) in Japanese patients.

Methods

We included patients from 23 institutions in Japan. We evaluated the objective response, radiographic progression‐free survival (PFS), overall survival (OS), and treatment‐related grade ≥ 3 (serious adverse events [SAEs]).

Results

We included 222 patients. The median age was 69 years (interquartile range 62–74 years), and 71% of the patients were male. Pancreas metastasis, lung metastases, prior cytokine therapy, and SAEs, were associated with objective response. The median PFS was 18 months. Liver metastases (hazard ratio [HR], 1.61), age ≥ 75 (HR, 0.48), previous resection of primary sites (HR, 0.47), and SAEs (HR, 0.47) were independent prognostic factors for PFS. Karnofsky Performance Status

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMaleMiddle AgedAgedFemaleNivolumabImmune Checkpoint InhibitorsPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

anti-PD-1 antibodynivolumabrenal cell carcinoma

Substanzen

NivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
  • Department of Urology, Sapporo Medical University School of Medicine, Sapporo, Japan.

ORCID-Profile: Leandro Blas, Masaki Shiota, Norihiko Tsuchiya, Naoya Masumori, Wataru Obara, Kiyohide Fujimoto, Kojiro Ohba, Shusuke Akamatsu, Yoshihiko Tomita, Shoichiro Mukai, Keiichi Ito

Förderung

  • Bristol-Myers Squibb
  • Ono Pharmaceutical

Zitieren

APA

Blas, L., Shiota, M., Miyake, H., Takahashi, M., Oya, M., Tsuchiya, N., Masumori, N., Matsuyama, H., Obara, W., Shinohara, N., Fujimoto, K., Nozawa, M., Ohba, K., Ohyama, C., Hashine, K., Akamatsu, S., Kamba, T., Mita, K., Gotoh, M., …, & SNiP-RCC Investigators (2023). Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study. International Journal of Urology. https://doi.org/10.1111/iju.15265

Vancouver

Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, et al. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study. International Journal of Urology. 2023. doi:10.1111/iju.15265

BibTeX
@article{Blas2023,
  author = {Blas, Leandro and Shiota, Masaki and Miyake, Hideaki and Takahashi, Masayuki and Oya, Mototsugu and Tsuchiya, Norihiko and Masumori, Naoya and Matsuyama, Hideyasu and Obara, Wataru and Shinohara, Nobuo and Fujimoto, Kiyohide and Nozawa, Masahiro and Ohba, Kojiro and Ohyama, Chikara and Hashine, Katsuyoshi and Akamatsu, Shusuke and Kamba, Tomomi and Mita, Koji and Gotoh, Momokazu and Tatarano, Shuichi and Fujisawa, Masato and Tomita, Yoshihiko and Mukai, Shoichiro and Ito, Keiichi and Tanegashima, Tokiyoshi and Tokunaga, Shoji and Eto, Masatoshi and SNiP-RCC Investigators, SNiP-RCC Investigators},
  title = {Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study},
  journal = {International Journal of Urology},
  year = {2023},
  doi = {10.1111/iju.15265}
}
Kostenlos starten →